title: Active tuberculosis during temsirolimus and bevacizumab treatment.
authors.affiliation: National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
authors.forename: Chia-Chi
authors.initials: CC
authors.lastname: Lin
authors.forename: Jann-Yuan
authors.initials: JY
authors.lastname: Wang
authors.forename: Yeong-Shiau
authors.initials: YS
authors.lastname: Pu
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D000077784:Axitinib; D000068258:Bevacizumab; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000382:microbiology* / Q000601:surgery; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007191:Indazoles / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000382:microbiology* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D014376:Tuberculosis / Q000188:drug therapy / Q000209:etiology*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007093:Imidazoles; D007191:Indazoles; D000068258:Bevacizumab; C401859:temsirolimus; D000077784:Axitinib; D020123:Sirolimus